Experimental Therapies for Yellow Fever

Overview

Journal Antiviral Res

Publisher Elsevier

Date 2012 Dec 15

PMID 23237991

Citations 15

Authors

Justin G Julander

Affiliations

Soon will be listed here.

Abstract

A number of viruses in the family Flaviviridae are the focus of efforts to develop effective antiviral therapies. Success has been achieved with inhibitors for the treatment of hepatitis C, and there is interest in clinical trials of drugs against dengue fever. Antiviral therapies have also been evaluated in patients with Japanese encephalitis and West Nile encephalitis. However, no treatment has been developed against the prototype flavivirus, yellow fever virus (YFV). Despite the availability of the live, attenuated 17D vaccine, thousands of cases of YF continue to occur each year in Africa and South America, with a significant mortality rate. In addition, a small number of vaccinees develop severe systemic infections with the 17D virus. This paper reviews current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection.

Citing Articles

Intensive Therapeutic Plasma Exchange-New Approach to Treat and Rescue Patients with Severe Form of Yellow Fever.

Ho Y, Nukui Y, Villaca P, Okazaki E, Tatsui N, Netto L Trop Med Infect Dis. 2025; 10(2).

PMID: 39998043 PMC: 11860207. DOI: 10.3390/tropicalmed10020039.

Novel Pyrazino[1,2-]indole-1,3(2,4)-dione Derivatives Targeting the Replication of Viruses: Structural and Mechanistic Insights.

Giannakopoulou E, Akrani I, Mpekoulis G, Frakolaki E, Dimitriou M, Myrianthopoulos V Viruses. 2024; 16(8).

PMID: 39205212 PMC: 11360281. DOI: 10.3390/v16081238.

Novel Lipophilic Hydroxamates Based on Spirocarbocyclic Hydantoin Scaffolds with Potent Antiviral and Trypanocidal Activity.

Pardali V, Giannakopoulou E, Mpekoulis G, Tsopela V, Panos G, Taylor M Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513957 PMC: 10385743. DOI: 10.3390/ph16071046.

Development of antibody-based assays for high throughput discovery and mechanistic study of antiviral agents against yellow fever virus.

Gao Z, Zhang L, Ma J, Jurado A, Hong S, Guo J Antiviral Res. 2020; 182:104907.

PMID: 32798604 PMC: 7426275. DOI: 10.1016/j.antiviral.2020.104907.

Antivirals against Chikungunya Virus: Is the Solution in Nature?.

Martins D, Santos I, de Oliveira D, Grosche V, Jardim A Viruses. 2020; 12(3).

PMID: 32121393 PMC: 7150839. DOI: 10.3390/v12030272.

References

LaSala P, Holbrook M . Tick-borne flaviviruses. Clin Lab Med. 2010; 30(1):221-35. DOI: 10.1016/j.cll.2010.01.002. View

Xiao S, Zhang H, Guzman H, Tesh R . Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis. 2001; 183(10):1437-44. DOI: 10.1086/320200. View

Julander J, Ennis J, Turner J, Morrey J . Treatment of yellow fever virus with an adenovirus-vectored interferon, DEF201, in a hamster model. Antimicrob Agents Chemother. 2011; 55(5):2067-73. PMC: 3088275. DOI: 10.1128/AAC.01635-10. View

Schafer B, Holzer G, Joachimsthaler A, Coulibaly S, Schwendinger M, Crowe B . Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One. 2011; 6(9):e24505. PMC: 3170363. DOI: 10.1371/journal.pone.0024505. View

Heinz F, Stiasny K . Flaviviruses and flavivirus vaccines. Vaccine. 2012; 30(29):4301-6. DOI: 10.1016/j.vaccine.2011.09.114. View

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

Wilckens V, Kannengiesser K, Hoxhold K, Frenkel C, Kucharzik T, Maaser C . The immunization status of patients with IBD is alarmingly poor before the introduction of specific guidelines. Scand J Gastroenterol. 2011; 46(7-8):855-61. DOI: 10.3109/00365521.2011.574734. View

Stock N, Boschetti N, Herzog C, Appelhans M, Niedrig M . The phylogeny of yellow fever virus 17D vaccines. Vaccine. 2011; 30(6):989-94. DOI: 10.1016/j.vaccine.2011.12.057. View

Meier K, Gardner C, Khoretonenko M, Klimstra W, Ryman K . A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009; 5(10):e1000614. PMC: 2749449. DOI: 10.1371/journal.ppat.1000614. View

10.

Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, Schmid P . Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 2009; 48(5):659-66. DOI: 10.1086/597006. View

11.

Turtle L, Griffiths M, Solomon T . Encephalitis caused by flaviviruses. QJM. 2012; 105(3):219-23. PMC: 3285924. DOI: 10.1093/qjmed/hcs013. View

12.

Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda J, Meynard J . Plasma HIV-RNA is the key determinant of long-term antibody persistence after Yellow fever immunization in a cohort of 364 HIV-infected patients. J Acquir Immune Defic Syndr. 2012; 59(4):360-7. DOI: 10.1097/QAI.0b013e318249de59. View

13.

Lam A, Murakami E, Espiritu C, Micolochick Steuer H, Niu C, Keilman M . PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010; 54(8):3187-96. PMC: 2916354. DOI: 10.1128/AAC.00399-10. View

14.

Paula T, Pablo R, Eugenia V, Pablo B, Sabino P, Jose M . New drug targets for hepatitis C and other Flaviviridae viruses. Infect Disord Drug Targets. 2009; 9(2):133-47. DOI: 10.2174/187152609787847749. View

15.

Dong H, Zhang B, Shi P . Flavivirus methyltransferase: a novel antiviral target. Antiviral Res. 2008; 80(1):1-10. PMC: 3214650. DOI: 10.1016/j.antiviral.2008.05.003. View

16.

Deng Y, Dai J, Ji G, Jiang T, Wang H, Yang H . A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One. 2011; 6(1):e16059. PMC: 3019176. DOI: 10.1371/journal.pone.0016059. View

17.

Monath T, Brinker K, CHANDLER F, Kemp G, Cropp C . Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg. 1981; 30(2):431-43. DOI: 10.4269/ajtmh.1981.30.431. View

18.

Eriksson B, Helgstrand E, Johansson N, Larsson A, MISIORNY A, Noren J . Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother. 1977; 11(6):946-51. PMC: 352108. DOI: 10.1128/AAC.11.6.946. View

19.

Peduto A, Massa A, Di Mola A, de Caprariis P, La Colla P, Loddo R . 2,3-Dihydro-1,2-Diphenyl-substituted 4H-Pyridinone derivatives as new anti Flaviviridae inhibitors. Chem Biol Drug Des. 2011; 77(6):441-9. DOI: 10.1111/j.1747-0285.2011.01102.x. View

20.

Stuyver L, McBrayer T, Tharnish P, Clark J, Hollecker L, Lostia S . Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother. 2006; 17(2):79-87. DOI: 10.1177/095632020601700203. View